



SpeedX Compact Respiratory Multiplex - now IVDR class D Certified
Upfront diagnosis. Combat seasonal testing surges with ease

SYDNEY, AUSTRALIA – (September 6, 2024). Innovative molecular diagnostic developer, SpeedX Pty. Ltd., have expanded their IVDR Certified Respiratory portfolio with the focused respiratory multiplex test, **PlexPCR®** Flu/RSV/SARS-CoV-2*. Now IVDR class D certified, this test is ideal for upfront diagnosis of clinically relevant seasonal respiratory viruses, enabling laboratories to triage samples for rapid turnaround.

"At SpeedX, we are very proud to be one of the first companies to achieve IVDR Class D certification for our respiratory 4-plex test. This significant achievement is a reflection of our commitment to quality and innovation," detailed Elisa Mokany, Chief Technology Officer & Founder, SpeedX.

PlexPCR® Flu/RSV/SARS-CoV-2 detects Influenza (A and B), Respiratory Syncytial Virus and SARS-CoV-2 virus in a single-well multiplex qPCR test. Prompt identification of these viral infections can be important for patient management. In addition, prioritising diagnosis of these common seasonal infections with a uniform testing approach can improve laboratory efficiency and productivity during seasonal testing surges.

"Seasonal respiratory surges are known to push the limits of testing capacity for many laboratories," explained Warwick Need, Director of Sales, SpeedX. *"Adopting **PlexPCR®** Flu/RSV/SARS-CoV-2 can ease the pressure, by funnelling all respiratory swabs into a single test."*

Affordable and efficient, **PlexPCR®** Flu/RSV/SARS-CoV-2 can easily cater to high testing volumes. Combining the SpeedX liquid handler, **PlexPrep®**, with open platform systems, provides a flexible workflow with scalable throughput. With this solution, laboratories can easily adapt to fluctuating testing demands.

*"For labs in Europe, this IVDR certification comes at the perfect time. Key results from the Australian flu season indicate that the European 2024/2025 season will be significant, putting considerable pressure on laboratories. Adopting **PlexPCR®** Flu/RSV/SARS-CoV-2 will alleviate these pressures in a cost-effective manner,"* says Colin Denver, CEO, SpeedX. *"Stay ahead of the game by adopting this solution today!"*

About SpeedX Pty Ltd

Founded in 2009, SpeedX is a global company with offices in Austin, London and Sydney, and distributors across Europe. SpeedX specializes in molecular diagnostic solutions that go beyond simple detection to also offer comprehensive information on antibiotic resistance. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeedX please see: <https://plexpcr.com>

* Product only available in the EU

Contact:

Michelle Howie
Associate Director | Global Strategic Marketing
michelleh@speedx.com.au
+61 499 743 199